STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMVT
  4. [Form 4] Immunovant, Inc. Insider Trading Activity

Immunovant (IMVT) Form 4: COO RSU vesting and tax share sale

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Immunovant, Inc. (IMVT) reported an insider transaction by its Chief Operating Officer, Melanie Gloria. On November 20, 2025, she sold 10,251 shares of common stock at a weighted average price of $23.54 per share and an additional 2,375 shares at a weighted average price of $23.97 per share.

These sales were made to cover tax withholding obligations related to the vesting and settlement of previously granted restricted stock units, following the company’s required “sell to cover” procedure. After these transactions, she beneficially owned 173,511 shares of Immunovant common stock directly.

Positive

  • None.

Negative

  • None.
Insider Gloria Melanie
Role Chief Operating Officer
Sold 12,626 shs ($298K)
Type Security Shares Price Value
Sale Common Stock 10,251 $23.54 $241K
Sale Common Stock 2,375 $23.97 $57K
Holdings After Transaction: Common Stock — 175,886 shares (Direct)
Footnotes (1)
  1. On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 27,489 of these RSUs vested on November 18, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.93 - $23.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.93 - $24.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gloria Melanie
(Last) (First) (Middle)
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
(Street)
NEW YORK NY 10018
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/20/2025 S 10,251(1) D $23.54(2) 175,886 D
Common Stock 11/20/2025 S 2,375(1) D $23.97(3) 173,511 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 27,489 of these RSUs vested on November 18, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.93 - $23.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.93 - $24.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Remarks:
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Tiago Girao, attorney-in-fact for Melanie Gloria 11/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Immunovant (IMVT) report in this Form 4?

The Chief Operating Officer, Melanie Gloria, reported sales of Immunovant common stock on November 20, 2025 to cover tax withholding obligations tied to RSU vesting.

How many Immunovant (IMVT) shares did the COO sell and at what prices?

She sold 10,251 shares at a weighted average price of $23.54 per share and 2,375 shares at a weighted average price of $23.97 per share.

Why did the Immunovant COO sell shares according to this Form 4?

The filing states the sales were made to cover tax withholding obligations from the vesting and settlement of restricted stock units under a required “sell to cover” arrangement.

How many Immunovant (IMVT) shares does the COO own after the reported trades?

After the reported transactions, the Chief Operating Officer beneficially owned 173,511 shares of Immunovant common stock directly.

What equity awards were involved in this Immunovant Form 4 filing?

The filing notes a prior grant of 109,956 restricted stock units, with 27,489 RSUs vesting on November 18, 2025, which triggered the tax-related share sales.

Were the Immunovant (IMVT) insider share sales discretionary?

No. The filing explains that the sales were mandated by the issuer’s election to satisfy tax withholding obligations through a “sell to cover” transaction, not a discretionary sale by the reporting person.